Use of materials for treatment of central nervous system lesions

Inactive Publication Date: 2006-09-28
SANBIO
View PDF13 Cites 48 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0021] In still another aspect, the invention relates to a method comprising: providing marrow-adherent stem cell-derived neuronal cells; and administering the marrow-adhe

Problems solved by technology

This can be important when trying to provide control over transplantation outcome and li

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of materials for treatment of central nervous system lesions
  • Use of materials for treatment of central nervous system lesions
  • Use of materials for treatment of central nervous system lesions

Examples

Experimental program
Comparison scheme
Effect test

example 1

MCAo Results—Weekly for Four Weeks Post-Transplantation

[0202] The test animals underwent the MCAo procedure as described above, and were evaluated weekly for four weeks port-transplantation with the following results.

[0203] EBST: For the weekly testing over the four weeks post-transplantation, overall ANOVA revealed significant main treatment effects (F2,21=57.06, p100,000>40,000) were also observed (p's<0.01). The motor asymmetry was significantly reduced in each of the four weeks post-transplantation compared to baseline (p's<0.0001), with the most robust recovery seen at one week post-transplantation (p's<0.0001), and with stable recovery displayed for the subsequent three weeks post-transplantation. Posthoc tests revealed that the significant reduction in motor asymmetry at 1 week post-transplantation did not differ across the three cell doses, but dose-dependent effects were seen at 2, 3 and 4 weeks post-transplantation (p's<0.05) (FIG. 2).

[0204] Bederson test: For the weekl...

example 2

MCAI Results—Weekly for Four Weeks Post-Transplantation

[0208] The test animals underwent the MCAI procedure as described above, and were evaluated weekly for four weeks post-transplantation with the following results.

[0209] EBST: For the weekly testing over the four weeks post-transplantation, overall ANOVA revealed significant main treatment effects (F2,24=76.30, p100,000>40,000) seen at 1 week post-transplantation (p's<0.05) (FIG. 12).

[0210] Bederson test: For the weekly testing over the four weeks post-transplantation, overall ANOVA revealed significant main treatment effects (F2,24=3.65, p0.005). Posthoc tests revealed that the highest dose of 200,000 cells produced better recovery than the low dose 40,000 cells at 3 and 4 weeks (p's0.05) (FIG. 14).

[0211] MWM Acquisition: For the weekly testing over the four weeks post-transplantation, overall ANOVA revealed no significant main treatment effects (F2,24=5.78-16, p>0.05) (FIG. 15). There appears to be a trend towards longer MW...

example 3

TGI Results—Weekly for Four Weeks Post-Transplantation

[0214] The test animals underwent the TGI procedure as described above, and were evaluated weekly for four weeks port-transplantation with the following results.

[0215] Bederson test: For the weekly testing over the four weeks post-transplantation, overall ANOVA revealed significant main treatment effects (F2,23=47.33, p100,000>40,000) were seen at 4 weeks post-transplantation (p's<0.05) (FIG. 22).

[0216] MWM Acquisition: For the weekly testing over the four weeks post-transplantation, overall ANOVA revealed significant main treatment effects (F2,23=9.88, p<0.001) (FIG. 23). However, this significant treatment effect was achieved only because the highest dose of 200,000 cells produced a transient significant improvement in acquiring the task at 1 week post-transplantation compared to the two other doses of 100,000 and 40,000 cells (p's<0.005). Thereafter, longer acquisition times at 2, 3 and 4 weeks post-transplantation compared...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed are methods and materials for treatment of central nervous system lesions. Preferred methods and materials comprise neuronal precursor cells and/or marrow adherent stem cell-derived neuronal cells.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Patent Application No. 60 / 659,335, filed Mar. 7, 2005.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The invention relates to treatment of central nervous system lesions, particularly to treatment of stroke. [0004] 2. Description of the Related Art [0005] Lesions can form in central nervous system (“CNS”) tissue for a number of reasons. One of the leading causes of CNS lesions is stroke. Stroke is characterized by the sudden loss of circulation to an area of the brain, resulting in a corresponding loss of neurologic function. Also called cerebrovascular accident or stroke syndrome, stroke is a nonspecific term encompassing a heterogeneous group of pathophysiologic causes, including thrombosis, embolism, and hemorrhage. Recent reports indicate an incidence exceeding 500,000 new strokes of all types per year. Stroke is a leading killer and disabler. Combining all ty...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/30C12N5/08
CPCA61K35/30A61P25/00A61P9/10
Inventor DEZAWA, MARIMORI, KEITA
Owner SANBIO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap